Faes Farma, S.A.

Equities

FAE

ES0134950F36

Pharmaceuticals

Market Closed - BME 11:35:26 2024-04-26 am EDT 5-day change 1st Jan Change
3.38 EUR +1.81% Intraday chart for Faes Farma, S.A. +6.12% +6.96%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
FAES FARMA : Q1 beat; full-year guidance re-affirmed Alphavalue
FAES FARMA : Q4 profitability exceeded expectations Alphavalue
Faes Farma, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
FAES FARMA : Mixed Q3; markets need more from Faes to be convinced Alphavalue
Faes Farma, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
FAES FARMA : A soft Q2, as expected; guidance maintained Alphavalue
Faes Farma, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
FAES FARMA : Increased R&D focus and inflationary pressures to hold back near-to-medium term earnings Alphavalue
FAES FARMA : A healthy start to 2023 Alphavalue
Faes Farma, S.A. completed the acquisition of NovoSci. CI
Faes Farma, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
FAES FARMA : 2022 guidance met + positive view maintained Alphavalue
Faes Farma, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Faes Farma, S.A. agreed to acquire NovoSci. CI
Roche’s Alzheimer’s failure has sector-wide implications Alphavalue
Faes Farma, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
FAES FARMA : Soft Q3, but 2022 guidance maintained Alphavalue
FAES FARMA : Another stronger quarter but maintained full-year outlook Alphavalue
Faes Farma, S.A. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Faes Farma, S.A. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
FAES FARMA : Strong Q1; but some moderation lies ahead Alphavalue
Faes Farma, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
FAES FARMA : A strong Q4 sums up a decent 2021 Alphavalue
Faes Farma, S.A. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
FAES FARMA : An overall strong Q3 Alphavalue
Chart Faes Farma, S.A.
More charts
Faes Farma SA is a Spain-based company engaged in the pharmaceutical industry. The Company specializes in the research, production, distribution and sale of prescription and generic drugs, over-the-counter (OTC) medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The Company’s research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome, among others. In addition, it provides animal nutrition products. The Company operates in Spain, Portugal, Chile and Mexico, among others. It controls a number of subsidiaries, such as Laboratorios Vitoria SA, Laboratorios Veris SA, Lazlo International SA, Ingaso Farm SLU, Esfion SA and Biotecnet I MAS D SA.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
3.38 EUR
Average target price
3.708 EUR
Spread / Average Target
+9.69%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. FAE Stock
  4. News Faes Farma, S.A.
  5. Faes Farma : Increased R&D focus and inflationary pressures to hold back near-to-medium term earnings